Novavax Q3 2026 Earnings Date & Estimates

Novavax (NASDAQ:NVAX) is a biotechnology company focused on the discovery, development and commercialization of vaccines. The company uses its recombinant protein-based vaccine platform and Matrix-M adjuvant technology to develop vaccines designed to stimulate targeted immune responses.

Novavax’s principal commercial product is its protein-based COVID-19 vaccine, marketed in various regions under the Nuvaxovid or Novavax COVID-19 Vaccine name. The vaccine has been authorized or approved in multiple markets, including the United States, Europe and other international jurisdictions, with availability and regulatory status varying by country. Novavax has also entered into strategic arrangements with other pharmaceutical companies to support the commercialization and distribution of its COVID-19 vaccine.

Founded in 1987 and headquartered in Gaithersburg, Maryland, Novavax conducts research and development activities in the United States and works with partners and regulators internationally. Its pipeline has included vaccine candidates targeting respiratory illnesses such as influenza, respiratory syncytial virus and combination respiratory vaccines. The company is led by Chief Executive Officer John C. Jacobs.